Related Experiment Video
Updated: May 18, 2026
13:08
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
Published on: September 9, 2012
Protein anticoagulants targeting factor VIIa-tissue factor complex: a comprehensive review
Karna Shah1, Riad Bayoumi, Yajnavalka Banerjee
1Department of Clinical Biochemistry, College of Medicine and Health Sciences, SQ University, Muscat, Oman.
Hematology (Amsterdam, Netherlands)
|September 18, 2012
Summary
New protein and peptide anticoagulants targeting Factor VIIa (FVIIa) offer improved specificity for treating blood clots. This review details their structure-activity relationships and clinical trial performance.
Area of Science:
- Biochemistry
- Pharmacology
- Hematology
Background:
- Current anticoagulants like heparin and warfarin lack specificity and have narrow therapeutic windows.
- Thromboembolic disorders necessitate the development of targeted anticoagulant therapies.
- Factor VIIa (FVIIa), in complex with tissue factor (TF), is a key upstream target in the coagulation cascade.
Purpose of the Study:
- To review protein/peptide anticoagulants targeting FVIIa or the TF-FVIIa complex.
- To delineate the structure-activity relationships of these novel anticoagulants.
- To present their current status and clinical trial performance.
Main Methods:
- Comprehensive literature review of studies on FVIIa/TF-FVIIa targeting anticoagulants.
- Analysis of structure-activity relationships for peptide and protein inhibitors.
- Evaluation of clinical trial data for efficacy and safety.
Main Results:
- Identified and appraised various peptide/protein anticoagulants targeting FVIIa/TF-FVIIa.
- Detailed structure-activity relationships for these agents.
- Summarized their performance in different clinical trial phases.
Conclusions:
- Targeting FVIIa/TF-FVIIa with protein/peptide anticoagulants represents a promising strategy for treating thromboembolic disorders.
- Further research into unexplored domains of these agents can enhance translational applications.
- These targeted anticoagulants may offer improved specificity and therapeutic windows over existing treatments.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:16Clot Retraction and Fibrinolysis
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
01:20Extrinsic and Intrinsic Pathways of Hemostasis
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which forms a...
01:09Coagulation
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...